{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:54:17Z","timestamp":1777514057653,"version":"3.51.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T00:00:00Z","timestamp":1350345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Van Buchem disease (VBD) is a rare bone sclerosing dysplasia caused by the lack of a regulatory element of the SOST gene, which encodes for sclerostin, an osteocyte-derived negative regulator of bone formation. We studied the demographic, clinical, biochemical, and densitometric features of 15 patients with VBD (12 adults and 3 children) and 28 related carriers of the gene mutation. The most common clinical findings in patients were facial palsy (100%) and various degrees of hearing impairment (93%); raised intracranial pressure had been documented in 20%. The clinical course of the disease appeared to stabilize in adulthood, with the majority of patients reporting no progression of symptoms or development of complications with time. Carriers of the disease had none of the clinical features or complications of the disease. Sclerostin could be detected in the serum in all but 1 VBD patients (mean 8.0\u2009pg\/mL; 95% confidence interval [CI], 4.9\u201311.0\u2009pg\/mL), and were lower than those of carriers (mean 28.7\u2009pg\/mL; 95% CI, 24.5\u201332.9\u2009pg\/mL; p\u2009&amp;lt;\u20090.001) and healthy controls (mean 40.0\u2009pg\/mL; 95% CI, 34.5\u201341.0\u2009pg\/mL; p\u2009&amp;lt;\u20090.). Serum procollagen type 1 amino-terminal propeptide (P1NP) levels were also significantly higher in adult patients (mean 96.0; 95% CI, 54.6\u2013137.4\u2009ng\/mL versus mean 47.8; 95% CI, 39.4\u201356.2\u2009ng\/mL, p\u2009=\u20090.003 in carriers and mean 37.8; 95% CI, 34.5\u201341.0\u2009ng\/mL, p\u2009=\u20090.028 in healthy controls) and declined with age. Bone mineral density (BMD) was markedly increased in all patients (mean Z-score 8.7\u2009\u00b1\u20092.1 and 9.5\u2009\u00b1\u20091.9 at the femoral neck and spine, respectively); BMD of carriers was significantly lower than that of patients but varied widely (mean Z-scores 0.9\u2009\u00b1\u20091.0 and 1.3\u2009\u00b1\u20091.5 at the femoral neck and spine, respectively). Serum sclerostin levels were inversely correlated with serum P1NP levels (r\u2009=\u2009\u20130.39, p\u2009=\u20090.018) and BMD values (femoral neck r\u2009=\u2009\u20130.69, p\u2009&amp;lt;\u20090.001; lumbar spine r\u2009=\u2009\u20130.78, p\u2009&amp;lt;\u20090.001). Our results show that there is a gene-dose effect of the VBD deletion on circulating sclerostin and provide further in vivo evidence of the role of sclerostin in bone formation in humans. The small amounts of sclerostin produced by patients with VBD may explain their milder phenotype compared to that of patients with sclerosteosis, in whom serum sclerostin is undetectable. \u00a9 2013 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.1794","type":"journal-article","created":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T13:02:00Z","timestamp":1350392520000},"page":"848-854","source":"Crossref","is-referenced-by-count":108,"title":["Van Buchem disease: Clinical, biochemical, and densitometric features of patients and disease carriers"],"prefix":"10.1093","volume":"28","author":[{"given":"Antoon H","family":"van Lierop","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neveen AT","family":"Hamdy","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martje E","family":"van Egmond","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egbert","family":"Bakker","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freek G","family":"Dikkers","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Socrates E","family":"Papapoulos","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,10,16]]},"reference":[{"key":"2024020318412722600_bib1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/00016925509170789","article-title":"An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris","volume":"44","author":"Van Buchem","year":"1955","journal-title":"Acta Radiol."},{"key":"2024020318412722600_bib2","first-page":"387","article-title":"Hyperostosis corticalis generalisata","volume":"33","author":"Van Buchem","year":"1962","journal-title":"Report of seven cases. Am J Med."},{"key":"2024020318412722600_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.0954-6820.1971.tb04373.x","article-title":"generalisata Eight new cases","volume":"189","author":"Van Buchem","year":"1971","journal-title":"Acta Med Scand."},{"key":"2024020318412722600_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-84-4-393","article-title":"The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals","volume":"4","author":"Beighton","year":"1976","journal-title":"Ann Intern Med."},{"key":"2024020318412722600_bib5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"van Bezooijen","year":"2004","journal-title":"J Exp Med."},{"key":"2024020318412722600_bib6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am J Hum Genet."},{"key":"2024020318412722600_bib7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum Mol Genet."},{"key":"2024020318412722600_bib8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.10401","article-title":"A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population","volume":"110","author":"Staehling-Hampton","year":"2002","journal-title":"Am J Med Genet."},{"key":"2024020318412722600_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","author":"Balemans","year":"2002","journal-title":"J Med Genet."},{"key":"2024020318412722600_bib10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1034\/j.1399-0004.2003.00036.x","article-title":"The natural history of sclerosteosis","volume":"63","author":"Hamersma","year":"2003","journal-title":"Clin Genet."},{"key":"2024020318412722600_bib11","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/jbmr.474","article-title":"Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover","volume":"26","author":"van Lierop","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020318412722600_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1399-0004.1984.tb00481.x","article-title":"The syndromic status of sclerosteosis and van Buchem disease","volume":"25","author":"Beighton","year":"1984","journal-title":"Clin Genet."},{"key":"2024020318412722600_bib13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1530\/EJE-10-0699","article-title":"Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls","volume":"163","author":"van Lierop","year":"2010","journal-title":"Eur J Endocrinol."},{"key":"2024020318412722600_bib14","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/jbmr.151","article-title":"Glucocorticoids are not always deleterious for bone","volume":"25","author":"van Lierop","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"6","key":"2024020318412722600_bib15","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ejpn.2012.03.002","article-title":"A rare cause of facial nerve palsy in children: hyperostosis corticalis generalisata (Van Buchem disease). Three new pediatric cases and a literature review","volume":"16","author":"van Egmond","year":"2012","journal-title":"Eur J Paediatr Neurol."},{"key":"2024020318412722600_bib16","first-page":"771","article-title":"Van Buchem's disease (hyperostosis corticalis generalisata familiaris)","volume":"90","author":"Fosmoe","year":"1968","journal-title":"A case report. Radiology."},{"key":"2024020318412722600_bib17","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/00000637-198805000-00011","article-title":"Van Buchem disease: surgical treatment of the mandible","volume":"20","author":"Schendel","year":"1988","journal-title":"Ann Plast Surg."},{"key":"2024020318412722600_bib18","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/jnnp.45.10.913","article-title":"Two cases of Van Buchem's disease","volume":"45","author":"Dixon","year":"1982","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"2024020318412722600_bib19","first-page":"237","article-title":"Van Buchem's disease (hyperostosis corticalis generalisata familiaris)","volume":"9","author":"Dyson","year":"1972","journal-title":"A case report. Br J Oral Surg."},{"key":"2024020318412722600_bib20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/pgmj.53.622.497","article-title":"Van Buchem disease","volume":"53","author":"Jacobs","year":"1977","journal-title":"Postgrad Med J."},{"key":"2024020318412722600_bib21","first-page":"227","article-title":"Van Buchem disease. Maxillofacial changes, diagnostic classification and general principles of treatment","volume":"48","author":"Scopelliti","year":"1999","journal-title":"Minerva Stomatol."},{"key":"2024020318412722600_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1086\/301721","article-title":"Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21","volume":"62","author":"Van Hul","year":"1998","journal-title":"Am J Hum Genet."},{"key":"2024020318412722600_bib23","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1086\/368277","article-title":"Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density","volume":"72","author":"Van Wesenbeeck","year":"2003","journal-title":"Am J Hum Genet."},{"key":"2024020318412722600_bib24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1148\/radiol.2531080011","article-title":"Case 150: Van Buchem disease (hyperostosis corticalis generalisata)","volume":"253","author":"Wengenroth","year":"2009","journal-title":"Radiology."},{"key":"2024020318412722600_bib25","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s00256-003-0675-4","article-title":"Van Buchem disease: lifetime evolution of radioclinical features","volume":"32","author":"Vanhoenacker","year":"2003","journal-title":"Skeletal Radiol."},{"key":"2024020318412722600_bib26","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3171\/jns.1993.78.3.0388","article-title":"Sclerosteosis: neurosurgical experience with 14 cases","volume":"78","author":"du Plessis","year":"1993","journal-title":"J Neurosurg."},{"key":"2024020318412722600_bib27","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1101\/gr.3437105","article-title":"Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease","volume":"15","author":"Loots","year":"2005","journal-title":"Genome Res."},{"key":"2024020318412722600_bib28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/0022034509338340","article-title":"Sclerostin in mineralized matrices and van Buchem disease","volume":"88","author":"van Bezooijen","year":"2009","journal-title":"J Dent Res."},{"key":"2024020318412722600_bib29","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J."},{"key":"2024020318412722600_bib30","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1210\/jc.2005-1235","article-title":"Bone mineral density in sclerosteosis; affected individuals and gene carriers","volume":"90","author":"Gardner","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318412722600_bib31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.1794","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/4\/848\/56564011\/1794_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/4\/848\/56564011\/1794_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:48:04Z","timestamp":1710341284000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/28\/4\/848-854\/7598738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,16]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,10,16]]},"published-print":{"date-parts":[[2013,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.1794","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,4,1]]},"published":{"date-parts":[[2012,10,16]]}}}